{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:23:16Z","timestamp":1790677396191,"version":"4.1.0"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"R1","license":[{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Alice and Y. T. Chen Center for Genetics and Genomics"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR065873"],"award-info":[{"award-number":["R01AR065873"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK105434-01A1"],"award-info":[{"award-number":["R01DK105434-01A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR065873"],"award-info":[{"award-number":["R01AR065873"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Arthritis, Muscle and Skin Diseases"},{"name":"National Institute of Arthritis, Muscle and Skin Diseases"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The focus of this review is the development of gene therapy for glycogen storage diseases (GSDs). GSD results from the deficiency of specific enzymes involved in the storage and retrieval of glucose in the body. Broadly, GSDs can be divided into types that affect liver or muscle or both tissues. For example, glucose-6-phosphatase (G6Pase) deficiency in GSD type Ia (GSD Ia) affects primarily the liver and kidney, while acid \u03b1-glucosidase (GAA) deficiency in GSD II causes primarily muscle disease. The lack of specific therapy for the GSDs has driven efforts to develop new therapies for these conditions. Gene therapy needs to replace deficient enzymes in target tissues, which has guided the planning of gene therapy experiments. Gene therapy with adeno-associated virus (AAV) vectors has demonstrated appropriate tropism for target tissues, including the liver, heart and skeletal muscle in animal models for GSD. AAV vectors transduced liver and kidney in GSD Ia and striated muscle in GSD II mice to replace the deficient enzyme in each disease. Gene therapy has been advanced to early phase clinical trials for the replacement of G6Pase in GSD Ia and GAA in GSD II (Pompe disease). Other GSDs have been treated in proof-of-concept studies, including GSD III, IV and V. The future of gene therapy appears promising for the GSDs, promising to provide more efficacious therapy for these disorders in the foreseeable future.<\/jats:p>","DOI":"10.1093\/hmg\/ddz133","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T15:10:22Z","timestamp":1559920222000},"page":"R31-R41","source":"Crossref","is-referenced-by-count":71,"title":["Gene therapy for glycogen storage diseases"],"prefix":"10.1093","volume":"28","author":[{"given":"Priya S","family":"Kishnani","sequence":"first","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA"},{"name":"Department of Molecular Genetics and Microbiology, Duke University, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodong","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D","family":"Koeberl","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA"},{"name":"Department of Molecular Genetics and Microbiology, Duke University, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,22]]},"reference":[{"key":"2019101710385729900_ref1","volume-title":"GeneReviews\u00ae","author":"Bali","year":"1993"},{"key":"2019101710385729900_ref2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.21037\/atm.2018.10.59","article-title":"Glycogen metabolism and glycogen storage disorders","volume":"6","author":"Kanungo","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"2019101710385729900_ref3","volume-title":"StatPearls","author":"Parikh","year":"2019"},{"key":"2019101710385729900_ref4","volume-title":"GeneReviews\u00ae","author":"Dagli","year":"1993"},{"key":"2019101710385729900_ref5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"ACMG Work Group on Management of Pompe Disease","year":"2006","journal-title":"Genet. Med."},{"key":"2019101710385729900_ref6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/GIM.0b013e3181e655b6","article-title":"Glycogen storage disease type III diagnosis and management guidelines","volume":"12","author":"Kishnani","year":"2010","journal-title":"Genet. Med."},{"key":"2019101710385729900_ref7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10545-016-9932-2","article-title":"Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome","volume":"39","author":"Sentner","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"2019101710385729900_ref8","volume-title":"GeneReviews\u00ae","author":"Magoulas","year":"1993"},{"key":"2019101710385729900_ref9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10545-009-9026-5","article-title":"Glycogen storage disease type IV: novel mutations and molecular characterization of a heterogeneous disorder","volume":"33","author":"Li","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"2019101710385729900_ref10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/0002-8223(93)92246-T","article-title":"Nutrition therapy for hepatic glycogen storage diseases","volume":"93","author":"Goldberg","year":"1993","journal-title":"J. Am. Diet. Assoc."},{"key":"2019101710385729900_ref11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/gim.2014.128","article-title":"Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics","volume":"16","author":"Kishnani","year":"2014","journal-title":"Genet. Med."},{"key":"2019101710385729900_ref12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"2019101710385729900_ref13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"2019101710385729900_ref14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review","volume":"106","author":"Patel","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"2019101710385729900_ref15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2017.09.008","article-title":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \u2018late-onset\u2019 GAA variant","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"2019101710385729900_ref16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: a systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"2019101710385729900_ref17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"key":"2019101710385729900_ref18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1540\/jsmr.54.100","article-title":"The impact of Pompe disease on smooth muscle: a review","volume":"54","author":"McCall","year":"2018","journal-title":"J. Smooth Muscle Res."},{"key":"2019101710385729900_ref19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","article-title":"Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy","volume":"123","author":"McIntosh","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"2019101710385729900_ref20","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1212\/WNL.0b013e3182553c11","article-title":"Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy","volume":"78","author":"Ebbink","year":"2012","journal-title":"Neurology"},{"key":"2019101710385729900_ref21","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.gt.3302774","article-title":"Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia","volume":"13","author":"Koeberl","year":"2006","journal-title":"Gene Ther."},{"key":"2019101710385729900_ref22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/mt.2008.72","article-title":"Gene delivery to the juvenile mouse liver using AAV2\/8 vectors","volume":"16","author":"Cunningham","year":"2008","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/hum.2009.157","article-title":"Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type ia","volume":"21","author":"Weinstein","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"2019101710385729900_ref24","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/mt.2010.64","article-title":"Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy","volume":"18","author":"Yiu","year":"2010","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10545-018-0223-y","article-title":"Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy","volume":"41","author":"Brooks","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"2019101710385729900_ref26","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10545-018-0248-2","article-title":"Letter to the editors: concerning \u2018Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia\u2019 by Lee et al","volume":"41","author":"Brooks","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"2019101710385729900_ref27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/mt.2016.35","article-title":"In vivo zinc finger nuclease-mediated targeted integration of a glucose-6-phosphatase transgene promotes survival in mice with glycogen storage disease type IA","volume":"24","author":"Landau","year":"2016","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref28","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/nar\/gkr1214","article-title":"Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases","volume":"40","author":"Perez-Pinera","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"2019101710385729900_ref29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ng1380","article-title":"Adeno-associated virus vectors integrate at chromosome breakage sites","volume":"36","author":"Miller","year":"2004","journal-title":"Nat. Genet."},{"key":"2019101710385729900_ref30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/hmg\/ddy343","article-title":"Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia","volume":"28","author":"Waskowicz","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"2019101710385729900_ref31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.omtm.2019.02.002","article-title":"Bezafibrate enhances AAV vector-mediated genome editing in glycogen storage disease type Ia","volume":"13","author":"Kang","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2019101710385729900_ref32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/hep.29176","article-title":"Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors","volume":"66","author":"Hosel","year":"2017","journal-title":"Hepatology"},{"key":"2019101710385729900_ref33","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/hep.25717","article-title":"Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy","volume":"56","author":"Lee","year":"2012","journal-title":"Hepatology"},{"key":"2019101710385729900_ref34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/mt.2008.15","article-title":"AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia","volume":"16","author":"Koeberl","year":"2008","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ymgme.2013.06.014","article-title":"The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia","volume":"110","author":"Lee","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"2019101710385729900_ref36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ymgme.2017.01.003","article-title":"Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-alpha activity restored are at risk of developing hepatic tumors","volume":"120","author":"Kim","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"2019101710385729900_ref37","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/hmg\/ddx097","article-title":"Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy","volume":"26","author":"Kim","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"2019101710385729900_ref38","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s10545-018-0199-7","article-title":"Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia","volume":"41","author":"Lee","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl 1","key":"2019101710385729900_ref39","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/BF02072088","article-title":"Glycogen storage disease type Ib: infectious complications and measures for prevention","volume":"152","author":"Wendel","year":"1993","journal-title":"Eur. J. Pediatr."},{"key":"2019101710385729900_ref40","first-page":"357","article-title":"Adeno-associated virus vectors for gene therapy","volume":"2","author":"Flotte","year":"1995","journal-title":"Gene Ther."},{"key":"2019101710385729900_ref41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.gt.3302869","article-title":"Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice","volume":"14","author":"Yiu","year":"2007","journal-title":"Gene Ther."},{"key":"2019101710385729900_ref42","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019101710385729900_ref43","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/mthe.2002.0563","article-title":"Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction","volume":"5","author":"Ding","year":"2002","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymthe.2005.08.006","article-title":"Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice","volume":"13","author":"Kiang","year":"2006","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/4751","article-title":"Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors","volume":"5","author":"Snyder","year":"1999","journal-title":"Nat. Med."},{"key":"2019101710385729900_ref46","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1073\/pnas.96.22.12725","article-title":"Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein","volume":"96","author":"Burton","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019101710385729900_ref47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref48","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","article-title":"Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers","volume":"11","author":"Raben","year":"2005","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1096\/fj.12-207472","article-title":"Adjunctive beta2-agonists reverse neuromuscular involvement in murine Pompe disease","volume":"27","author":"Li","year":"2013","journal-title":"FASEB J."},{"key":"2019101710385729900_ref51","doi-asserted-by":"crossref","first-page":"14018","DOI":"10.1038\/mtm.2014.18","article-title":"Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease","volume":"1","author":"Wang","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2019101710385729900_ref52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"2019101710385729900_ref53","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1073\/pnas.0405042101","article-title":"Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood\u2013brain barrier","volume":"101","author":"Urayama","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2019101710385729900_ref54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-dose liver-targeted gene therapy for Pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2019101710385729900_ref55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1006\/mthe.2000.0031","article-title":"Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver","volume":"1","author":"Wang","year":"2000","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref56","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/sj.gt.3302142","article-title":"Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B","volume":"11","author":"Harding","year":"2004","journal-title":"Gene Ther."},{"key":"2019101710385729900_ref57","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"2019101710385729900_ref58","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/hum.2008.010","article-title":"Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice","volume":"19","author":"Ziegler","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"2019101710385729900_ref59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1089\/hum.2011.063","article-title":"Immunodominant, liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease","volume":"23","author":"Zhang","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"2019101710385729900_ref60","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine Pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref61","article-title":"Immunomodulatory, liver depot gene therapy for Pompe disease","author":"Bond","year":"2017","journal-title":"Cell. Immunol."},{"key":"2019101710385729900_ref62","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/mt.2008.133","article-title":"Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy","volume":"16","author":"Sun","year":"2008","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/hum.2018.016","article-title":"Systemic delivery of AAVB1-GAA clears glycogen and prolongs survival in a mouse model of Pompe disease","volume":"30","author":"Keeler","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"2019101710385729900_ref64","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/hum.2015.103","article-title":"Copackaged AAV9 vectors promote simultaneous immune tolerance and phenotypic correction of Pompe disease","volume":"27","author":"Doerfler","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"2019101710385729900_ref65","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0006-291X(02)00566-1","article-title":"Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression","volume":"294","author":"Barash","year":"2003","journal-title":"Bochem. Biophys. Res. Comm."},{"key":"2019101710385729900_ref66","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2006.08.001","article-title":"Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II","volume":"14","author":"Sun","year":"2006","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref67","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"2019101710385729900_ref68","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ymthe.2018.06.023","article-title":"Correction of biochemical abnormalities and improved muscle function in a phase I\/II clinical trial of clenbuterol in Pompe disease","volume":"26","author":"Koeberl","year":"2018","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref69","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.omtm.2019.01.006","article-title":"Intravenous injection of an AAV-PHP.B vector encoding human acid alpha-glucosidase rescues both muscle and CNS defects in murine Pompe disease","volume":"12","author":"Lim","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2019101710385729900_ref70","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2006.09.022","article-title":"Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?","volume":"46","author":"Demo","year":"2007","journal-title":"J. Hepatol."},{"key":"2019101710385729900_ref71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005176-199703000-00008","article-title":"Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature","volume":"24","author":"Labrune","year":"1997","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"2019101710385729900_ref72","first-page":"168","article-title":"Liver transplantation in patients with type IIIa glycogen storage disease, cirrhosis and hepatocellular carcinoma","volume":"111","author":"Iglesias Jorquera","year":"2019","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"2019101710385729900_ref73","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00431-015-2546-0","article-title":"Skeletal and cardiac muscle involvement in children with glycogen storage disease type III","volume":"174","author":"Mogahed","year":"2015","journal-title":"Eur. J. Pediatr."},{"key":"2019101710385729900_ref74","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/BF00443106","article-title":"Cardiac involvement in glycogen storage disease type III","volume":"148","author":"Moses","year":"1989","journal-title":"Eur. J. Pediatr."},{"key":"2019101710385729900_ref75","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF01744800","article-title":"Cardiomyopathy of glycogen storage disease type III","volume":"8","author":"Carvalho","year":"1993","journal-title":"Heart Vessels"},{"key":"2019101710385729900_ref76","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ymthe.2017.12.019","article-title":"Rescue of GSDIII phenotype with gene transfer requires liver- and muscle-targeted GDE expression","volume":"26","author":"Vidal","year":"2018","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref77","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.ymthe.2018.04.023","article-title":"Inhibition of glycogen synthase II with RNAi prevents liver injury in mouse models of glycogen storage diseases","volume":"26","author":"Pursell","year":"2018","journal-title":"Mol. Ther."},{"key":"2019101710385729900_ref78","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/adc.43.231.548","article-title":"Glycogen storage disease type IV, amylopectinosis","volume":"43","author":"Levin","year":"1968","journal-title":"Arch. Dis. Child."},{"key":"2019101710385729900_ref79","volume-title":"GeneReviews\u00ae","author":"Magoulas","year":"1993"},{"key":"2019101710385729900_ref80","volume-title":"Scriver\u2019s Online Metabolic & Molecular Bases of Inherited Disease","author":"Chen","year":"2009"},{"key":"2019101710385729900_ref81","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1212\/01.WNL.0000138429.11433.0D","article-title":"Clinical and genetic heterogeneity of branching enzyme deficiency (glycogenosis type IV)","volume":"63","author":"Bruno","year":"2004","journal-title":"Neurology"},{"key":"2019101710385729900_ref82","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1566524024605815","article-title":"The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies","volume":"2","author":"Moses","year":"2002","journal-title":"Curr. Mol. Med."},{"key":"2019101710385729900_ref83","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1172\/JCI118517","article-title":"Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene","volume":"97","author":"Bao","year":"1996","journal-title":"J. Clin. Invest."},{"key":"2019101710385729900_ref84","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1089\/hum.2016.099","article-title":"Systemic correction of murine glycogen storage disease type IV by an AAV-mediated gene therapy","volume":"28","author":"Yi","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"2019101710385729900_ref85","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/jnnp-2011-301593","article-title":"Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry","volume":"83","author":"Lucia","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2019101710385729900_ref86","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/humu.9434","article-title":"McArdle disease: the mutation spectrum of PYGM in a large Italian cohort","volume":"27","author":"Bruno","year":"2006","journal-title":"Hum. Mutat."},{"key":"2019101710385729900_ref87","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/humu.22806","article-title":"McArdle disease: update of reported mutations and polymorphisms in the PYGM gene","volume":"36","author":"Nogales-Gadea","year":"2015","journal-title":"Hum. Mutat."},{"key":"2019101710385729900_ref88","first-page":"120","article-title":"A multi-parametric protocol to study exercise intolerance in McArdle\u2019s disease","volume":"34","author":"Ricci","year":"2015","journal-title":"Acta Myol."},{"key":"2019101710385729900_ref89","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ncpneuro0913","article-title":"McArdle disease: what do neurologists need to know?","volume":"4","author":"Lucia","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"2019101710385729900_ref90","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1249\/MSS.0000000000000812","article-title":"Exercise and preexercise nutrition as treatment for McArdle disease","volume":"48","author":"Nogales-Gadea","year":"2016","journal-title":"Med. Sci. Sports Exerc."},{"key":"2019101710385729900_ref91","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.nmd.2007.10.006","article-title":"Adenovirus and adeno-associated virus-mediated delivery of human myophosphorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle\u2019s disease: expression and re-expression of glycogen phosphorylase","volume":"18","author":"Howell","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"2019101710385729900_ref92","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1016\/S0021-9258(18)62582-7","article-title":"Control of phosphorylase activity in a muscle glycogen particle. I. Isolation and characterization of the protein\u2013glycogen complex","volume":"245","author":"Meyer","year":"1970","journal-title":"J. Biol. Chem."},{"key":"2019101710385729900_ref93","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/01913123.2011.601404","article-title":"Glycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment","volume":"35","author":"Hicks","year":"2011","journal-title":"Ultrastruct. Pathol."},{"key":"2019101710385729900_ref94","first-page":"1521","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Chen","year":"2001"},{"key":"2019101710385729900_ref95","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/WCO.0000000000000484","article-title":"Update on new muscle glycogenosis","volume":"30","author":"Laforet","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"2019101710385729900_ref96","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1242\/jcs.184770","article-title":"Danon disease\u2014dysregulation of autophagy in a multisystem disorder with cardiomyopathy","volume":"129","author":"Rowland","year":"2016","journal-title":"J. Cell Sci."},{"key":"2019101710385729900_ref97","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/MOH.0000000000000474","article-title":"Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor","volume":"26","author":"Dale","year":"2019","journal-title":"Curr. Opin. Hematol."},{"key":"2019101710385729900_ref98","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/s00431-002-1004-y","article-title":"Glycogen storage disease type I: indications for liver and\/or kidney transplantation","volume":"161","author":"Labrune","year":"2002","journal-title":"Eur. J. Pediatr."},{"key":"2019101710385729900_ref99","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3928\/01913913-20140813-01","article-title":"Ocular and histologic findings in a series of children with infantile Pompe disease treated with enzyme replacement therapy","volume":"51","author":"Prakalapakorn","year":"2014","journal-title":"J. Pediatr. Ophthalmol. Strabismus"}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/advance-article-pdf\/doi\/10.1093\/hmg\/ddz133\/29019928\/ddz133.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/28\/R1\/R31\/30160332\/ddz133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/28\/R1\/R31\/30160332\/ddz133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T17:54:40Z","timestamp":1663610080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/28\/R1\/R31\/5520922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,22]]},"references-count":99,"journal-issue":{"issue":"R1","published-online":{"date-parts":[[2019,6,22]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddz133","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,6,22]]}}}